---
title: "Zoetis Inc. (ZTS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ZTS.US.md"
symbol: "ZTS.US"
name: "Zoetis Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-19T21:29:10.663Z"
locales:
  - [en](https://longbridge.com/en/quote/ZTS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ZTS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ZTS.US.md)
---

# Zoetis Inc. (ZTS.US)

## Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.zoetis.com](https://www.zoetis.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: C (0.45)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 48 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.88% |  |
| Net Profit YoY | 7.35% |  |
| P/B Ratio | 10.08 |  |
| Dividend Ratio | 2.65% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 32582409330.96 |  |
| Revenue | 9531000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 67.75% | A |
| Profit Margin | 28.03% | A |
| Gross Margin | 71.71% | A |
| Revenue YoY | 2.88% | C |
| Net Profit YoY | 7.35% | C |
| Total Assets YoY | 7.49% | B |
| Net Assets YoY | -30.55% | E |
| Cash Flow Margin | 104.42% | C |
| OCF YoY | 2.88% | C |
| Turnover | 0.65 | B |
| Gearing Ratio | 78.67% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zoetis Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.88%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "7.35%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "10.08",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.65%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "32582409330.96",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "9531000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "67.75%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "28.03%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "71.71%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "2.88%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "7.35%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.49%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-30.55%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "104.42%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "2.88%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.65",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "78.67%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 12.19 | 18/190 | 26.54 | 21.16 | 19.30 |
| PB | 10.08 | 180/190 | 15.16 | 13.61 | 10.25 |
| PS (TTM) | 3.42 | 84/190 | 7.31 | 5.97 | 5.45 |
| Dividend Yield | 2.65% | 16/190 | 1.69% | 1.57% | 1.25% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **20**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 45% |
| Overweight | 3 | 15% |
| Hold | 8 | 40% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 78.92 |
| Highest Target | 190.00 |
| Lowest Target | 127.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ZTS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ZTS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ZTS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ZTS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**